Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech

Animal trials of Bharat Biotech International Limited’s Covid-19 vaccine candidate, Covaxin, have been successful and the results showed the shot’s “remarkable immunogenicity and protective efficacy” in the Phase I clinical trials in India, the drugmaker has said.

“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” Bharat Biotech tweeted on Friday.

Bharat Biotech had received approval from the Central Drugs Standard Control Organisation to conduct the Phase-II trials earlier this month. It had announced in June that it successfully developed Covaxin in collaboration with ICMR and the National Institute of Virology (NIV).

As of now –
Total Coronavirus Cases: 4,663M
Total recovery: 3,624M
Total Death: 77,537

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s